Non-executive director Chen Jiarong reduces his holding of 6,489,500 shares of MEITU (01357) at a price of approximately HK$2.13 per share.

16/09/2024

The latest information from the Hong Kong Stock Exchange shows that on September 13, non-executive director Chen Jiarong reduced his holdings in Meitu Company (01357) by 6.4895 million shares, with an average price of 2.134 Hong Kong dollars per share, totaling approximately 13.8486 million Hong Kong dollars.

According to the latest information from the Hong Kong Stock Exchange, on September 13th, non-executive director Chan Kar Wing reduced his holdings of MEITU (01357) by 6.4895 million shares, with an average price of 2.134 Hong Kong dollars per share, totaling approximately 13.8486 million Hong Kong dollars. After the reduction, the latest number of shares held is 0.

CISI FIN: Maintains "Buy" rating for BEAUTYFARM MED (02373) with a target price of HK$45.

Open Securities: The trend of "wealth management" for deposits is accelerating, and the advantages of comprehensive service-oriented banks are expanding.

JP Morgan is optimistic about the potential of the CRISPR gene editing pipeline and has initiated coverage with an "overweight" rating and a target price of $70 USD.

CISI FIN: Maintains "Buy" rating for BEAUTYFARM MED (02373) with a target price of HK$45.

Open Securities: The trend of "wealth management" for deposits is accelerating, and the advantages of comprehensive service-oriented banks are expanding.

JP Morgan is optimistic about the potential of the CRISPR gene editing pipeline and has initiated coverage with an "overweight" rating and a target price of $70 USD.